Nxera Pharma to Book $1.8 Million Milestone from Centessa Collaboration

The latest update is out from Sosei Group ( (JP:4565) ).

Nxera Pharma, a Tokyo-listed biopharma group specializing in specialty medicines and GPCR structure-based drug discovery, operates commercial and R&D hubs in Japan, the UK, Switzerland and South Korea. The company targets high-value markets in Japan and the wider APAC region, combining its NxWave platform with alliances to broaden its pipeline of innovative therapies.

Nxera will receive a US$1.8 million milestone payment from Centessa Pharmaceuticals after Centessa achieved an early development milestone with its investigational orexin receptor 2 agonist, ORX489, for neuropsychiatric disorders. The payment, to be booked as first-quarter 2026 revenue, underscores the financial and strategic value of Nxera’s research collaboration model and validates its role in enabling partner-led drug development.

The most recent analyst rating on (JP:4565) stock is a Hold with a Yen804.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.

More about Sosei Group

Nxera Pharma is a technology-driven biopharmaceutical company focused on developing new specialty medicines for patients with unmet medical needs in Japan and globally. Leveraging its NxWave GPCR structure-based drug discovery platform, the company runs an agile commercial operation in Japan, markets several launched products, and advances an extensive pipeline through internal programs and partnerships across APAC and major European hubs.

Average Trading Volume: 871,503

Technical Sentiment Signal: Sell

Current Market Cap: Yen77.65B

For a thorough assessment of 4565 stock, go to TipRanks’ Stock Analysis page.